Shares of Hims & Hers Health (NYSE: HIMS) experienced a significant surge in value following an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker’s popular GLP-1 weight loss drugs. This unexpected partnership has left many investors wondering if it’s still a good time to invest in the company. Let’s delve deeper into the recent developments and analyze the potential for future growth.
Hims & Hers Health and Novo Nordisk have had a rocky relationship in the past, marked by a failed commercial partnership and legal disputes. Novo Nordisk accused Hims of illegally selling compounded versions of its drugs, leading to the termination of their initial agreement. Despite these challenges, the companies have now come to a new understanding that involves Hims offering Novo Nordisk’s Ozempic injections and Wegovy pills on its platform. This move signifies a fresh start and the resolution of previous conflicts, as the lawsuit between the two parties will be dropped.
The decision to collaborate once again with Hims highlights the reach and potential of the telemedicine platform. While this partnership is expected to drive growth, it may come at a slightly lower gross margin. Nevertheless, the removal of legal obstacles and the endorsement from Novo Nordisk bode well for Hims’ future prospects.
Even after the recent stock price surge, Hims remains attractively valued, trading at a forward price-to-earnings ratio below 20 times based on analyst estimates for 2026 and below 15 times based on 2027 projections. With revenue climbing by 28% in the last quarter and opportunities for international expansion on the horizon, the company is still positioned for growth. However, given the history of volatility in its relationship with Novo Nordisk, investors are advised to approach with caution and consider smaller positions to mitigate risks.
In conclusion, the renewed partnership between Hims & Hers Health and Novo Nordisk presents a promising opportunity for both companies. While there may be challenges ahead, the potential for long-term growth and the resolution of past conflicts paint a positive outlook for Hims. Investors should closely monitor the developments and consider the implications of this new agreement before making any investment decisions.
This article was originally published by The Motley Fool and has been rewritten for a WordPress platform, incorporating the key points and original HTML tags for reference.
